HUE046924T2 - Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra - Google Patents

Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra

Info

Publication number
HUE046924T2
HUE046924T2 HUE14756991A HUE14756991A HUE046924T2 HU E046924 T2 HUE046924 T2 HU E046924T2 HU E14756991 A HUE14756991 A HU E14756991A HU E14756991 A HUE14756991 A HU E14756991A HU E046924 T2 HUE046924 T2 HU E046924T2
Authority
HU
Hungary
Prior art keywords
barth
syndrome
prevention
compositions
treatment
Prior art date
Application number
HUE14756991A
Other languages
English (en)
Hungarian (hu)
Inventor
D Travis Wilson
Mark Bamberger
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of HUE046924T2 publication Critical patent/HUE046924T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HUE14756991A 2013-03-01 2014-02-28 Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra HUE046924T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771534P 2013-03-01 2013-03-01
US201361771642P 2013-03-01 2013-03-01
US201361839753P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
HUE046924T2 true HUE046924T2 (hu) 2020-03-30

Family

ID=51428869

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14756991A HUE046924T2 (hu) 2013-03-01 2014-02-28 Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra

Country Status (9)

Country Link
US (5) US9687519B2 (OSRAM)
EP (2) EP2961420B1 (OSRAM)
JP (4) JP6518197B2 (OSRAM)
CN (3) CN115990242A (OSRAM)
CA (1) CA2916880C (OSRAM)
DK (1) DK2961420T3 (OSRAM)
ES (1) ES2750258T3 (OSRAM)
HU (1) HUE046924T2 (OSRAM)
WO (1) WO2014134554A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312066A (zh) * 2011-12-09 2017-11-03 康德生物医疗技术公司 芳香族阳离子肽及其用途
CN115990242A (zh) 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
WO2016094791A1 (en) * 2014-12-12 2016-06-16 University Of Washington Methods for treating and preventing cardiomyopathy
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
EP3898653A4 (en) * 2018-12-18 2022-08-24 Stealth BioTherapeutics Inc. ANALOGS TARGETING MITOCHONDRIAL DISEASES

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU2002365425A1 (en) 2001-08-06 2003-09-02 Vanderbilt University An apparatus and methods for using biological material to discriminate an agent
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CN101440124B (zh) 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
AU2004210013A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070265216A1 (en) * 2005-10-05 2007-11-15 Gross Richard W Enhanced medical treatment in diabetic cardiomyopathy
AU2007237899A1 (en) * 2006-04-18 2007-10-25 Cortendo Invest, Ab Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
CA2688125A1 (en) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
WO2008156654A2 (en) 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
WO2009149307A2 (en) 2008-06-04 2009-12-10 San Diego State University Research Foundation Compositions and methods for restoring mitochondrial electron transfer function
EA020091B1 (ru) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2419513A2 (en) 2009-04-17 2012-02-22 The Salk Institute For Biological Studies Regulation of aging by modulation of mitochondrial function
US20120046363A1 (en) 2009-05-11 2012-02-23 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
CN105031605A (zh) 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
SMT202300433T1 (it) * 2009-08-24 2024-01-10 Stealth Biotherapeutics Inc Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
US8719939B2 (en) 2009-12-31 2014-05-06 Mcafee, Inc. Malware detection via reputation system
CA2786280A1 (en) 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP4643749B1 (ja) 2010-02-03 2011-03-02 昭和電工株式会社 表面被覆サーメット部材の耐酸化膜形成用の処理液
CA2790823A1 (en) 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
WO2011116007A1 (en) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP2013532124A (ja) 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
MX2013001469A (es) 2010-08-06 2013-05-14 Edison Pharmaceuticals Inc Tratamiento de enfermedades mitocondriales con naftoquinonas
JP2013538799A (ja) 2010-08-06 2013-10-17 アンペア ライフ サイエンシーズ，インコーポレイテッド ビタミンｋを用いたミトコンドリア病の処置
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
WO2012129427A2 (en) 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same
CN106913860A (zh) 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
CN104094119A (zh) * 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
HK1204988A1 (en) 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CN104203262A (zh) * 2012-02-23 2014-12-10 康奈尔大学 芳香族阳离子肽及其用途
US20150266946A1 (en) 2012-10-09 2015-09-24 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
WO2014066419A2 (en) * 2012-10-22 2014-05-01 Stealth Peptides International, Inc. Methods for reducing risks associated with heart failure and factors associated therewith
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CN115990242A (zh) * 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
CA2916977A1 (en) * 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
WO2014134554A1 (en) 2014-09-04
JP6918046B2 (ja) 2021-08-11
CA2916880C (en) 2021-02-09
US9687519B2 (en) 2017-06-27
US11083771B2 (en) 2021-08-10
EP2961420B1 (en) 2019-09-11
JP2016511259A (ja) 2016-04-14
ES2750258T3 (es) 2020-03-25
JP2019147815A (ja) 2019-09-05
JP2022116008A (ja) 2022-08-09
US12268724B2 (en) 2025-04-08
CA2916880A1 (en) 2014-09-04
DK2961420T3 (da) 2019-10-07
CN115990241A (zh) 2023-04-21
US20240156892A1 (en) 2024-05-16
JP7381652B2 (ja) 2023-11-15
CN105407906A (zh) 2016-03-16
US20210401923A1 (en) 2021-12-30
JP7072692B2 (ja) 2022-05-20
US11771734B2 (en) 2023-10-03
EP2961420A1 (en) 2016-01-06
US11083772B2 (en) 2021-08-10
US20200345803A1 (en) 2020-11-05
JP6518197B2 (ja) 2019-05-22
EP2961420A4 (en) 2016-08-17
EP3626252A1 (en) 2020-03-25
JP2021098704A (ja) 2021-07-01
CN115990242A (zh) 2023-04-21
US20160228487A1 (en) 2016-08-11
US20180147251A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL279752A (en) Polycyclic compounds and use thereof in the treatment of immune disorders
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
HUE046924T2 (hu) Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
HUE039997T2 (hu) Szulfamoilpirrolamid származékok és alkalmazásuk hepatitisz B kezelésére szolgáló gyógyszerekként
HUE040446T2 (hu) Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
ZA201507155B (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
IL240213A0 (en) Sulfamoyl-arylamides and their use as drugs for the treatment of jaundice b
HUE037347T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
HUE066811T2 (hu) Izoxazolin kompozíciók és azok felhasználása parazitafertõzések megelõzésében és kezelésében állatokban
HUE037343T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
HUE036224T2 (hu) C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra
ZA201506759B (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
SI2956471T1 (sl) Sestava za zaviralca il-1beta in njegova uporaba
HUE051020T2 (hu) A ceramid szintjei a fertõzések kezelésében és megelõzésében
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
IL243192B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
EP3065548A4 (en) Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases
PT2862576T (pt) Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite
TH1601002624A (th) องค์ประกอบสำหรับใช้ในการป้องกันหรือรักษาการติดเชื้อ urt ในทารกหรือเด็ก เล็กที่มีความเสี่ยง